American Diabetes Association
Browse
dc22-0717-File003[AU].pdf (488.64 kB)

Associations of New-onset Atrial Fibrillation with Risks of Cardiovascular Disease, Chronic Kidney Disease and Mortality among Patients with Type 2 Diabetes

Download (488.64 kB)
figure
posted on 2022-08-19, 14:57 authored by Tingting Geng, Yi Wang, Qi Lu, Yan-Bo Zhang, Jun-Xiang Chen, Yan-Feng Zhou, Zhenzhen Wan, Kunquan Guo, Kun Yang, Liegang Liu, Gang Liu, An Pan

  

Objective: Atrial fibrillation (AF) frequently occurs in patients with type 2 diabetes (T2D); however, the longitudinal associations of new-onset AF with risks of adverse health outcomes in patients with T2D remains unclear. This study aimed to determine the associations of new-onset AF with subsequent risks of atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and mortality among patients with T2D.

Research design and methods: We included 16,551 adults with T2D, who were free of cardiovascular diseases (CVD) and CKD at recruitment from the UK Biobank study. Time-varying Cox regression models were used to assess the associations of incident AF with subsequent risks of incident ASCVD, heart failure, CKD, and mortality.

Results: Among the patients with T2D, 1394 developed AF and 15,157 remained free of AF during the follow-up. Over median follow-up of 10.7-11.0 years, we documented 2872 ASCVD, 852 heart failure, 1548 CKD, and 1776 total death (409 CVD deaths). Among patients with T2D, those with incident AF had higher risks of ASCVD (HR, 1.85; 95% CI, 1.59-2.16), heart failure (HR, 4.40; 95% CI, 3.67-5.28), CKD (HR, 1.68; 95% CI, 1.41-2.01),all-cause mortality (HR, 2.91; 95% CI, 2.53-3.34), and CVD mortality (HR, 3.75; 95% CI, 2.93-4.80) compared with those without incident AF.

Conclusion: Patients with T2D who developed AF had significantly increased risks of developing subsequent adverse cardiovascular events, CKD, and mortality. Our data underscore the importance of strategies of AF prevention to reduce macro- and microvascular complications in patients with T2D.

Funding

AP is funded by grants from the National Nature Science Foundation of China (81930124 and 82021005) and the Fundamental Research Funds for the Central Universities (2021GCRC075). GL is funded by grants from the National Nature Science Foundation of China (82073554) and the Fundamental Research Funds for the Central Universities (2021GCRC076). TG is funded by grants from the China Postdoctoral Science Foundation (2021M691129). Role of the Funder/Sponsor: The Funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC